Skip to content

Effect of a fibre-enriched versus standard pediatric tube feed on the intestinal flora, gastrointestinal function and nutritional status of 7-12 year old children.

Effect of a fibre-enriched versus standard pediatric tube feed on the intestinal flora, gastrointestinal function and nutritional status of 7-12 year old children.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22400
Enrollment
27
Registered
2006-06-23
Start date
2003-09-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1. Tube fed

Interventions

Duration intervention: 7 Months. Two paediatric tube feeds: 1. Fibre-enriched
2. Standard (fibre-free).

Sponsors

Numico Research B.V.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children: 1. male and female subjects, aged 7-12 years, who are expected to need tube feeding for at least 8 months; 2. >12 years of age, but with an age-weight status comparable to 7-12 years (21-45kg) are eligible; 3. currently tube fed with a fibre-free formula for the last 2 (or more) weeks; 4. for whom tube feeding contributes to at least 50% of total energy intake; 5. who are stable with respect to their disease/pathological condition; 6. whose daily nutritional intake is stable during the study period; 7. written parental informed consent.

Exclusion criteria

Exclusion criteria: Children: 1. with Cow’s Milk Allergy, inflammatory bowel disease or bowel resection; 2. requiring a fibre-free diet; 3. on antibiotic therapy during the 2 weeks preceding the study; 4. using laxative therapy other than polyethylene glycol or paraffin oil during the 2 weeks preceding the study; 5. with acute diarrhoea during the 2 weeks preceding the study; 6. consuming more than 1 serving of yoghurt or fermented dairy product during the 2 weeks preceding the study; 7. receiving supplementation with Fe and/or any of the other monitored micronutrients during the month prior to inclusion; 8. with disease associated gastro-intestinal disorders (short-bowel disease, malabsorption, cystic fibrosis); 9. with known dislipoprotidemia; 10. participating simultaneously in another clinical trial.

Design outcomes

Primary

MeasureTime frame
Gut microflora.

Secondary

MeasureTime frame
1. Bowel function: stool frequency, consistency and reduction of laxative use; 2. Gastro-intestinal intolerance (eg: bloating, abdominal pain, nausea); 3. Nutritional status, assessed by measuring anthropometrics, micronutrient status and body composition.

Contacts

Public ContactJane McKenzie

Numico Research B.V., PO Box 7005

Jane.McKenzie@Numico-Research.nl+31 (0)317 467800

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)